Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Duane Nash, insider at Immunic

Duane Nash Insider Information

Chairman of Immunic
Duane Nash, M.D., J.D., M.B.A, joined Immunic’s board as its chairman in 2019. Since April 2020, he has temporarily assumed the role of Executive Chairman.
From 2012 to 2019, Dr. Nash served in various leadership roles at Vital Therapies (Nasdaq: VTL), most recently as its Chief Executive Officer. Additional roles included Medical Director, Executive Vice President, Chief Business Officer and President. Prior to joining Vital Therapies, Dr. Nash held various positions at Wedbush PacGrowth Life Sciences, an investment bank, where he worked from 2009 to 2012, most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, which was acquired by Wedbush in 2009.
Dr. Nash also practiced law from 2002 to 2008, most recently at the law firm of Davis Polk & Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash served on the board of directors of Aerpio Pharmaceuticals (Nasdaq: ARPO) from 2012 to 2017, and Akebia Therapeutics (Nasdaq: AKBA) from 2013 to 2018.
Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California, San Francisco.

What is Duane Nash's net worth?

The estimated net worth of Duane Nash is at least $127,124.64 as of May 12th, 2022. Dr. Nash owns 22,032 shares of Immunic stock worth more than $127,125 as of May 22nd. This net worth evaluation does not reflect any other investments that Dr. Nash may own. Additionally, Dr. Nash receives a salary of $362,640.00 as Chairman at Immunic. Learn More about Duane Nash's net worth.

How old is Duane Nash?

Dr. Nash is currently 51 years old. There are 5 older executives and no younger executives at Immunic. The oldest executive at Immunic is Dr. Andreas Muehler Ph.D., M.D., Chief Medical Officer, who is 58 years old. Learn More on Duane Nash's age.

What is Duane Nash's salary?

As the Chairman of Immunic, Inc., Dr. Nash earned a total compensation package of $2,199,796.00 in 2020. Dr. Nash earned a salary of $231,139.00, options awards of $1,837,157.00, non-equity compensation of $131,500.00, and no other miscellaneous compensation. There are 3 executives that earn more than Dr. Nash. The highest earning executive at Immunic is Dr. Daniel Vitt, CEO, Pres & Director, who commands a salary of $609,450.00 per year. Learn More on Duane Nash's salary.

How do I contact Duane Nash?

The corporate mailing address for Dr. Nash and other Immunic executives is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. Immunic can also be reached via phone at (332) 255-9818 and via email at [email protected] Learn More on Duane Nash's contact information.

Has Duane Nash been buying or selling shares of Immunic?

During the past quarter, Duane Nash has bought $50,300.00 in shares of Immunic stock. As far as recent transactions, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on Duane Nash's trading history.

Who are Immunic's active insiders?

Immunic's insider roster includes Duane Nash (Chairman), Daniel Vitt (CEO), and Glenn Whaley (Insider). Learn More on Immunic's active insiders.

Are insiders buying or selling shares of Immunic?

In the last twelve months, Immunic insiders bought shares 6 times. They purchased a total of 22,500 shares worth more than $125,615.00. The most recent insider tranaction occured on May, 12th when CFO Glenn Whaley bought 3,000 shares worth more than $15,240.00. Insiders at Immunic own 12.1 % of the company. Learn More about insider trades at Immunic.

Information on this page was last updated on 5/12/2022.

Duane Nash Insider Trading History at Immunic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Buy10,000$5.03$50,300.0022,032View SEC Filing Icon  
5/12/2021Buy4,000$12.75$51,000.0014,032View SEC Filing Icon  
12/4/2019Sell4,400$6.96$30,624.0022,362View SEC Filing Icon  
See Full Table

Duane Nash Buying and Selling Activity at Immunic

This chart shows Duane Nash's buying and selling at Immunic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunic Company Overview

Immunic logo
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $5.77
Low: $5.17
High: $5.78

50 Day Range

MA: $9.08
Low: $5.15
High: $12.25

2 Week Range

Now: $5.77
Low: $4.96
High: $15.12

Volume

279,881 shs

Average Volume

346,261 shs

Market Capitalization

$176.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.